{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:10:10Z","timestamp":1794928210758,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Akero Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41591-021-01425-3","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T12:03:27Z","timestamp":1625745807000},"page":"1262-1271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":366,"title":["Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial"],"prefix":"10.1038","volume":"27","author":[{"given":"Stephen A.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Ruane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley L.","family":"Freilich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmee","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Behling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"de Temple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3599-0297","authenticated-orcid":false,"given":"Erik J.","family":"Tillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Rolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-1626","authenticated-orcid":false,"given":"Kitty","family":"Yale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"1425_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328\u2013357 (2018).","journal-title":"Hepatology"},{"key":"1425_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","volume":"140","author":"CD Williams","year":"2011","unstructured":"Williams, C. D. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 124\u2013131 (2011).","journal-title":"Gastroenterology"},{"key":"1425_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"1425_CR4","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","volume":"158","author":"BA Neuschwander-Tetri","year":"2020","unstructured":"Neuschwander-Tetri, B. A. Therapeutic landscape for NAFLD in 2020. Gastroenterology 158, 1984\u20131998 (2020).","journal-title":"Gastroenterology"},{"key":"1425_CR5","doi-asserted-by":"publisher","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","volume":"11","author":"EJ Tillman","year":"2020","unstructured":"Tillman, E. J. & Rolph, T. FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front. Endocrinol. (Lausanne) 11, 601290 (2020).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"1425_CR6","doi-asserted-by":"crossref","unstructured":"Geng, L., Lam, K. S. L. & Xu, A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat. Rev. Endocrinol. 16, 654\u2013667 (2020).","DOI":"10.1038\/s41574-020-0386-0"},{"key":"1425_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich, G. et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333\u2013340 (2013).","journal-title":"Cell Metab."},{"key":"1425_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar, S. et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23, 427\u2013440 (2016).","journal-title":"Cell Metab."},{"key":"1425_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/oby.22344","volume":"27","author":"ED Charles","year":"2019","unstructured":"Charles, E. D. et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity (Silver Spring) 27, 41\u201349 (2019).","journal-title":"Obesity (Silver Spring)"},{"key":"1425_CR10","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","volume":"392","author":"A Sanyal","year":"2019","unstructured":"Sanyal, A. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 392, 2705\u20132717 (2019).","journal-title":"Lancet"},{"key":"1425_CR11","unstructured":"Kunder, R. et al. Multiple Doses of an anti-FGFR1\/KLB bispecific antibody (BFKB8488A) are associated with a decrease in hepatic fat in patients in NAFLD. American Association for the Study of Liver Diseases (AASLD): The Liver Meeting, LP-8 (2019)."},{"key":"1425_CR12","unstructured":"Wong, C. et al. A bispecific antibody to FGFR1\/KLB, BFKB8488A, improves lipid profile, markers of fibrogenesis and liver health in patients with type 2 diabetes\u2013preliminary results from a phase 1b study. American Association for the Study of Liver Diseases (AASLD): The Liver Meeting, P-2310 (2019)."},{"key":"1425_CR13","doi-asserted-by":"crossref","unstructured":"DePaoli, A. et al. NGM313, a novel activator of b-klotho\/FGFR1c, improves insulin resistance and reduces hepatic fat in obese, nondiabetic subjects. American Diabetes Association https:\/\/diabetes.diabetesjournals.org\/content\/68\/Supplement_1\/140-LB (2019).","DOI":"10.2337\/db19-140-LB"},{"key":"1425_CR14","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1210\/en.2016-1917","volume":"158","author":"S Stanislaus","year":"2017","unstructured":"Stanislaus, S. et al. A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward \u03b2-klotho, and enhanced efficacy in mice and cynomolgus monkeys. Endocrinology 158, 1314\u20131327 (2017).","journal-title":"Endocrinology"},{"key":"1425_CR15","doi-asserted-by":"publisher","first-page":"100057","DOI":"10.1016\/j.xcrm.2020.100057","volume":"1","author":"A Kaufman","year":"2020","unstructured":"Kaufman, A., Abuqayyas, L., Denney, W. S., Tillman, E. J. & Rolph, T. AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients. Cell Rep. Med. 1, 100057 (2020).","journal-title":"Cell Rep. Med."},{"key":"1425_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","volume":"146","author":"JE Lambert","year":"2014","unstructured":"Lambert, J. E., Ramos-Roman, M. A., Browning, J. D. & Parks, E. J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146, 726\u2013735 (2014).","journal-title":"Gastroenterology"},{"key":"1425_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/ijo.2014.76","volume":"39","author":"JM Gallego-Escuredo","year":"2015","unstructured":"Gallego-Escuredo, J. M. et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int. J. Obes. (Lond.) 39, 121\u2013129 (2015).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"1425_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/db08-0392","volume":"58","author":"J Xu","year":"2009","unstructured":"Xu, J. et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250\u2013259 (2009).","journal-title":"Diabetes"},{"key":"1425_CR19","doi-asserted-by":"crossref","unstructured":"Harrison, S. A. et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology 160, 219\u2013231 (2020).","DOI":"10.1053\/j.gastro.2020.08.004"},{"key":"1425_CR20","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","volume":"391","author":"SA Harrison","year":"2018","unstructured":"Harrison, S. A. et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391, 1174\u20131185 (2018).","journal-title":"Lancet"},{"key":"1425_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1177\/1756283X16656735","volume":"9","author":"J Patel","year":"2016","unstructured":"Patel, J. et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Ther. Adv. Gastroenterol. 9, 692\u2013701 (2016).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"1425_CR22","first-page":"303","volume":"5","author":"SA Harrison","year":"2019","unstructured":"Harrison, S. A. et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology 5, 303 (2019).","journal-title":"Hepatology"},{"key":"1425_CR23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.30418","volume":"70","author":"EM Brunt","year":"2019","unstructured":"Brunt, E. M. et al. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials. Hepatology 70, 522\u2013531 (2019).","journal-title":"Hepatology"},{"key":"1425_CR24","doi-asserted-by":"publisher","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","volume":"287","author":"MA Lanaspa","year":"2012","unstructured":"Lanaspa, M. A. et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress. J. Biol. Chem. 287, 40732\u201340744 (2012).","journal-title":"J. Biol. Chem."},{"key":"1425_CR25","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/hep.23717","volume":"52","author":"A Afzali","year":"2010","unstructured":"Afzali, A., Weiss, N. S., Boyko, E. J. & Ioannou, G. N. Association between serum uric acid level and chronic liver disease in the United States. Hepatology 52, 578\u2013589 (2010).","journal-title":"Hepatology"},{"key":"1425_CR26","doi-asserted-by":"publisher","first-page":"e0137302","DOI":"10.1371\/journal.pone.0137302","volume":"10","author":"MJ Nielsen","year":"2015","unstructured":"Nielsen, M. J. et al. Markers of collagen remodeling detect clinically significant fibrosis in chronic hepatitis c patients. PLoS ONE 10, e0137302 (2015).","journal-title":"PLoS ONE"},{"key":"1425_CR27","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.ajpath.2011.02.035","volume":"178","author":"MS Shafiei","year":"2011","unstructured":"Shafiei, M. S., Shetty, S., Scherer, P. E. & Rockey, D. C. Adiponectin regulation of stellate cell activation via PPAR\u03b3-dependent and -independent mechanisms. Am. J. Pathol. 178, 2690\u20132699 (2011).","journal-title":"Am. J. Pathol."},{"key":"1425_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/liv.12896","volume":"36","author":"KM Irvine","year":"2016","unstructured":"Irvine, K. M. et al. The enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int. 36, 370\u2013377 (2016).","journal-title":"Liver Int."},{"key":"1425_CR29","unstructured":"Bayly, G. R. in Clinical Biochemistry (eds. Marshall, W. J., Lapsley, M., Day, A. P. & Ayling, R. M.) 702\u2013736 (Elsevier, 2014)."},{"key":"1425_CR30","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184\u20132196 (2019).","journal-title":"Lancet"},{"key":"1425_CR31","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison, S. A. et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394, 2012\u20132024 (2019).","journal-title":"Lancet"},{"key":"1425_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367\u2013378; quiz e14\u2013e15 (2015).","journal-title":"Gastroenterology"},{"key":"1425_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/sj.ijo.0803720","volume":"32","author":"KD Hall","year":"2008","unstructured":"Hall, K. D. What is the required energy deficit per unit weight loss? Int. J. Obes. (Lond.) 32, 573\u2013576 (2008).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"1425_CR34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.celrep.2018.03.070","volume":"23","author":"TM Frayling","year":"2018","unstructured":"Frayling, T. M. et al. A common allele in FGF21 associated with sugar intake is associated with body shape, lower total body-fat percentage, and higher blood pressure. Cell Rep. 23, 327\u2013336 (2018).","journal-title":"Cell Rep."},{"key":"1425_CR35","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01425-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:35:43Z","timestamp":1733942143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01425-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01425-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740449504.793591782","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"11 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.L.F., G.N., P.J.R., R.P. and S.A.H. received research funding from Akero Therapeutics as part of the current study. C.A.B. and C.H. are employees of research partners who received payment from Akero Therapeutics for services as part of the current study. A.C., B.D.T., E.F., E.J.T., K.Y. and T.P.R. are employees of Akero Therapeutics. A.C., B.D.T., E.F., E.J.T., K.Y., S.A.H. and T.P.R. own stock and\/or stock options of Akero Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}